All In Biotech

Free tool

FAERS Monitor: Amitiza

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 19, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 021908 or its brand name (Amitiza, Lubiprostone). Reports on generic versions are filed under their own applications.

Reports

9,556

Serious

6,379

67% of reports

Hospitalization

3,148

Death reported

972

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • nausea803
  • dyspnoea641
  • diarrhoea633
  • constipation584
  • drug ineffective568
  • fatigue544
  • pain500
  • headache498
  • dizziness457
  • fall409
  • vomiting409
  • off label use350
  • chronic kidney disease334
  • malaise323
  • pyrexia305

Reports by year received

View as table
YearReports
200618
200798
2008163
2009182
2010215
2011210
2012298
2013315
2014404
2015633
2016905
2017788
2018910
2019883
2020736
2021591
2022435
2023439
2024442
2025476
2026415

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,044,603 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
chronic kidney diseaseSignal3349.78.72,600
constipationSignal5845.95.52,394
fallSignal4092.72.5445
dyspnoeaSignal6412.52.3587
nauseaSignal8032.22.1567
diarrhoeaSignal6332.22.0405
dizzinessSignal4572.01.8239
pyrexia3051.91.7140
vomiting4091.91.7182
pain5001.81.6179
headache4981.71.6164
malaise3231.61.578
fatigue5441.51.4106
drug ineffective5680.90.92
off label use3500.90.86

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.